MedImmune it has enhanced its leadership team to guide the company's expanded product pipeline and core scientific research. Jacqueline Hall has been appointed global vice president, product development team leadership; Lorin Roskos, Ph.D. has been appointed vice president and global head of pharmacokinetics (PK), pharmacodynamics (PD), and bioanalysis in translational sciences, and Beth Wensley has been appointed vice president, project management. In addition, Erik-Jan Dekker, Ph.D. joined the organization as vice president, international regulatory affairs, vaccines, and Reginald Seeto, M.D., joins as vice president, global strategic marketing and portfolio management.

"It is imperative that we have strong leaders who can channel the  
continued growth of our product portfolio, particularly as we seek to  
build out the organization globally," said David M. Mott, chief  
executive officer and president. "Jacqui, Lorin, Beth, E-J and Reg  
have the innate talent, industry experience and drive for results that  
will contribute to MedImmune's continued leadership in biologics."

Based at the Cambridge, UK site, Ms. Hall is responsible for the  
strategic leadership of global product development teams that are  
responsible for the generation and execution of development plans for biologics products. She joined Cambridge Antibody Technology (CAT), now MedImmune, in 2006 as vice president, project management. Previously, Ms. Hall served as project leader at GlaxoSmithKline where she was responsible for the strategic development of product candidates from selection through to market launch. She has also held positions at SmithKline Beecham, Pharmaco-LSR and Schering-Plough.

Dr. Roskos is responsible for managing and integrating preclinical and clinical PK/PD and bioanalytical groups at the company's sites in MD, CA and in England. Dr. Roskos joined the company in 2008 after a year at AstraZeneca as executive director of R&D. Dr. Roskos had previously spent six years at Abgenix, Inc., as the head of PK and toxicology, and has prior experience in PK and drug metabolism at Amgen and Eli Lilly.

Ms. Wensley oversees the global project management team that provides strategic project management in driving forward the product development teams and the overall product development portfolio. Ms. Wensley joined MedImmune in 2001, and has previously served as senior director, CA operations; director, supply chain operations; and associate director, project management.

Based in the Netherlands as the company's new vice president,  
international regulatory affairs, vaccines, Dr. Dekker will lead  
MedImmune's expansion overseas. In his previous position at Baxter  
Healthcare, he was the global senior director, regulatory affairs,  
biologics, responsible for worldwide vaccine and biosurgery marketing authorization applications. Prior to Baxter, Dr. Dekker was the director of regulatory affairs globally at Laboratoire Francais du  
Fractionnement et des Biotechnologies in France.

Dr. Reginald Seeto is responsible for providing strategic guidance on investment decisions and managing commercialization efforts for new products in various stages of development. In his previous position at Organon International, he was the vice president of global marketing, fertility, immunology, oncology and vaccines. Previously, Dr. Seeto was the executive director of marketing at Boehringer Ingelheim Pharmaceuticals and served as an engagement manager at McKinsey & Co.

Hospira

1Q Revenues: $888.7 million (+14%)

1Q Earnings: $65.4 million (loss of $29.4 million 1Q07)

Comments: In the Americas, pharmaceuticals revenues grew was 11% to $462.6 million. However, the "Other Pharmaceuticals" unit, which  
includes injectables and contract revenues, dropped 3% to $121.9  
million. Asia Pacific pharmaceuticals revenue was $49.7 million  
(+58%). 1Q07 loss includes $66.2 million of acquired in-process R&D  
charges related to the Mayne Pharma acquisition.

Patricia Williams has been appointed to the position of vice 
president, commercial operations, Kendle. In this newly created 
position, Ms. Williams will provide leadership for global contract 
execution and negotiation with the company's biopharmaceutical 
customers, including master service agreements and changes in scope. She will be based in Kendle's European headquarters in Crowthorne, England and will report directly to Chris Bergen, chief operating officer.

"I am pleased to welcome Patricia to this key leadership role," said 
Bergen. "As global contracts of $10 million or more continue to drive 
double-digit growth within the CRO industry, her expertise will be 
invaluable in developing and negotiating innovative contract solutions that support both Kendle's profitable growth and meet the changing and long-term needs of our customers."

Ms. Williams has a decade of global contract management expertise and joins the company from one of the world's largest CROs, serving most recently as vice president, global contracts. Her experience also includes serving as assistant global director, Proposal Development and Contract Management for another global CRO.

Kendle

1Q Revenues: $158.8 million (+20%)

1Q Earnings: $5.6 million (+33%)

Comments: The company achieved record service revenues of $114.1  
million and record new business awards of $180 million, both up 20%.  
Total business authorizations were $917 million (+31%). Net service  
revenues by geographic region were 46% in North America, 42% in  
Europe, 7% in Latin America and 5% in the Asia/Pacific region.